Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients
Autor: | In Kyoon Lyoo, Sujung J. Yoon, Perry F. Renshaw, Andrew L. Stoll, Bruce M. Cohen, Charlotte A. Haws, J. Eric Jensen, Melissa A. Daniels, Nicolas R. Bolo, James R. Rusche |
---|---|
Rok vydání: | 2008 |
Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Magnetic Resonance Spectroscopy Phosphocreatine Acetates Neuropsychological Tests Ph changes Gastroenterology Rating scale Internal medicine Triacetyluridine medicine Humans Pharmacology (medical) Bipolar disorder Psychiatry Uridine Depression (differential diagnoses) Depressive symptoms Brain Chemistry Psychiatric Status Rating Scales Pharmacology Depressive Disorder medicine.diagnostic_test business.industry Significant difference Magnetic resonance imaging Hydrogen-Ion Concentration Middle Aged medicine.disease Magnetic Resonance Imaging Antidepressive Agents Mitochondria Psychiatry and Mental health Female business |
Zdroj: | Experimental and Clinical Psychopharmacology. 16:199-206 |
ISSN: | 1936-2293 1064-1297 |
DOI: | 10.1037/1064-1297.16.3.199 |
Popis: | Eleven patients with bipolar depression were given doses of up to 18 g per day of triacetyluridine (TAU) over 6 weeks to test the effect of uridine on symptoms of depression via Montgomery-Asberg Depression Rating Scale (MADRS; Asberg, Montgomery, Perris, Schalling, & Sedvall, 1978) scores and on cellular bioenergetics using phosphorus magnetic resonance spectroscopic imaging (31P-MRSI). All patients and comparison participants (n = 9) completed baseline 31P-MRSI scans, and 9 patients completed posttherapy scans. The percentage changes for MADRS scores (Week 2, -23.8; Week 3, -34.9; Week 4, -42.5) and the time effects of TAU on MADRS scores (Week 2, z = -2.07, p = .039; Week 3, z = -4.28, p < .001; Week 4, z = -4.54, p < .001) may reflect TAU effects on early symptom improvement. TAU responders (patients who had a 50% or greater reduction in MADRS scores from baseline at any time) demonstrated a significant difference from nonresponders in pH changes from baseline (effect size = 150). These results suggest that TAU treatment may decrease symptoms of depression and improve mitochondrial functioning. |
Databáze: | OpenAIRE |
Externí odkaz: |